Discontinuous deletions at 11q23 in B cell chronic lymphocytic leukemia

B-cell Chronic Lymphocytic Leukemia

Purpose: To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). Methods: Weanalyzed thenatureofmalignantB-CLLB cells and their interactions with the microenvironment. Results: B-CLL is a malignancy of a mantle zonebased subpopulation of anergic, self-reactive, activated CD51 B cells devoted to the production of polyreactive natural ...

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Alemtuzumab, a humanized monoclonal antibody, is thought to destroy cancer cells through immune system stimulation or apoptosis induction (programmed cell death). In case series studies using alemtuzumab as salvage therapy, about a third of patients with B-cell chronic lymphocytic leukemia (B-CLL), who were otherwise refractory to chemotherapy, improved. Anti-tumour activity was also observed w...

Deletions at 11q23 in different lymphoma subtypes.

BACKGROUND AND OBJECTIVES Chromosome band 11q23 is frequently deleted in various types of neoplasm. The region represented by yeast artificial chromosome (YAC) clone 755b11 at 11q23 has been shown to be the minimal common region of deletion in mantle cell lymphoma (MCL) and B-cell chronic lymphocytic leukemia (B-CLL). The aim of the study was to determine the frequencies of 11q23 deletion in di...

Chromosome abnormalities and RB1 gene deletions in chronic lymphocytic leukemia.

Personalized Drug Analysis in B Cell Chronic Lymphocytic Leukemia Patients

BACKGROUND B cell chronic lymphocytic leukemia (B-CLL) is the most common adult leukemia in the Western world. Although therapeutic advances have notably improved the outcome for many patients, B-CLL remains an incurable disease. The purpose of this study was to search for therapeutic drugs based on altered pathways in individual patients. MATERIAL AND METHODS Genes from microarray data were ma...